Skip to main content

Rapid tranquilisation

Medical Professionals

Professional Reference articles are designed for health professionals to use. They are written by UK doctors and based on research evidence, UK and European Guidelines. You may find one of our health articles more useful.

See also the separate Bipolar Disorder article.

The National Institute for Health and Care Excellence (NICE) 2015 guidelines define rapid tranquilisation (RT) as the use of medication to calm/lightly sedate the service user, reduce the risk to self and/or others and achieve an optimal reduction in agitation and aggression, thereby allowing a thorough psychiatric evaluation to take place and allowing comprehension and response to spoken messages throughout the intervention.

The aim should be to maintain the service user in as calm a state as possible whilst being able to maintain communication with them. It is recognised that RT may lead to deep sedation/anaesthesia, although this is not the overt intention1 .

Always consider any antecedents to the the acute situation: has the situation been exacerbated by poor communication, lack of privacy, overcrowding, boredom, long waiting times or lack of information? The British Association for Psychopharmacology and the National Association of Psychiatric Intensive Care and Low Secure Units developed a joint evidence-based consensus guideline of 2018 that recommends de-escalation as a preventative measure2 .

NICE guidance recommends that after an RT episode, the patient should be invited to record their own experience of the incident3 .

Continue reading below

Initial assessment

This should ideally include:

  • Full history - from as many sources as possible.

  • Legal status - establish whether the patient is already under the Mental Capacity Act.

  • If the patient is already on a psychiatric ward (informally or under section 5(2)), RT treatment can be given under common law.

  • Mental state examination.

  • Previous psychiatric history.

  • Full medication history - including alcohol and substance abuse.

  • Physical examination (if safe to do so).

  • Recent drug screen (if available).

Always think of organic causes (particularly if there are fluctuating levels of consciousness, disorientation, visual hallucinations) or any previous head injury.

  • RT should be humane, ethical, legal and clinically effective.

  • Consider the presence of any advance care planning.

  • A primary concern in violent situations should be for the safety of all. Decisions made in good faith by medical staff in the acute situation, taken to avert serious risk, can be sanctioned by common law without recourse to the Mental Capacity Act. All treatment should be reasonable and proportionate. Where possible, treatment without consent should be under one of the treatment sections of the Mental Capacity Act (usually section 3).

Continue reading below

Assess risks

Risks are increased in children, frail elderly, pregnancy, Lewy body dementia, or by concurrent medical illness.

These risks are:

  • Loss of consciousness.

  • Airway obstruction.

  • Respiratory depression ± arrest .

  • Hypotension or cardiovascular collapse.

  • Cardiac arrest.

  • Seizure.

  • Extrapyramidal side-effects (EPSEs) or neuroleptic malignant syndrome.

Exclude medical contra-indications to RT (eg, cardiac disease or respiratory disorders) and ensure facilities for basic CPR and flumazenil are available.

Oral regimens1

  • Oral medication is preferred to parenteral drugs whenever possible.

  • NICE suggests lorazepam, olanzapine or haloperidol (if using haloperidol, consider an anticholinergic drug).

  • Do not use 'drug cocktails' and keep to within a manufacturer's recommended doses (use the minimum effective dose) whenever possible. NICE accepts that there may be rare occasions when the dosage range recommended by the manufacturer may need to be exceeded. In this situation, a risk-benefit analysis should be made and recorded. More intensive monitoring will then be required than if the dosage had been within the recommended range.

  • Lorazepam should be considered first for non-psychotic behavioural disturbance - oral if possible but intramuscular if necessary.

  • Behavioural disturbance in the context of psychosis should be treated with lorazepam combined with an antipsychotic.

  • Olanzapine (and risperidone) should be avoided in patients with dementia, due to an increased risk of stroke and death.

Continue reading below

Parenteral regimens1 2

  • The risks and benefits of the intramuscular versus the intravenous route will have to be weighed up for individual patients, ie difficulties of siting the cannula versus speed of onset of action.

  • Oral therapy should be commenced as soon as feasible.

  • Never mix lorazepam with other drugs in the same syringe. Using olanzapine with lorazepam concurrently is not recommended. Ideally give an antimuscarinic drug (eg, procyclidine) if haloperidol is given4 .

Chart for rapid tranquilisation


Time to maximum plasma concentration

Approximate half-life



15-60 minutes

10-36 hours


oral solution

2-6 hours

10-36 hours



2-6 hours

10-36 hours



60-90 minutes

12-16 hours



2 hours

12 hours




5-8 hours

32-50 hours



15-45 minutes

32-50 hours




1-2 hours

24 hours



1-2 hours

24 hours



1-2 hours

24 hours


  • Blood pressure/pulse/respiratory rate every 5 minutes, temperature every 30 minutes and look for evidence of dystonia.

  • Transfer (accompanied by staff) only when the patient has been stable for at least 30 minutes (calm and cardiovascular and respiratory observations stable).


Ensure at least the following minimum is recorded1 :

Reasons for using RT

  • Legal situation (ie which part of the Mental Health Act used).

  • Physical assessment - any medical hazards recognised.

  • Patient's diagnosis.

  • Drugs given - in what sequence and dosage.

  • Outcome.

  • Monitoring chart and ongoing plan.


Discuss, as a significant event, whether the need for RT could have been anticipated and prevented. Discuss the patient's account if available.

Prevention: de-escalation2

There is a paucity of evidence for de-escalation but its practice is accepted as good clinical practice and is thought to be associated with fewer recurrences of aggressive or violent behaviours5 . It varies across units but key components may include:

  • The establishment of verbal contact.

  • Avoiding being provocative.

  • Being concise.

  • Listening closely to the patient

  • Respecting the patient and their personal space.

  • Negotiating and trying to agree or agreeing to disagree.

  • Offering choices and optimism.

  • Setting clear limits.

  • Identifying the wants or feelings of the patient.

  • Debriefing the patient and staff.

  • Proactive de-escalation planning.

Further reading and references

  1. Violence and aggression: short-term management in mental health, health and community settings; NICE Guideline (May 2015)
  2. Patel MX, Sethi FN, Barnes TR, et al; Joint BAP NAPICU evidence-based consensus guidelines for the clinical management of acute disturbance: De-escalation and rapid tranquillisation. J Psychopharmacol. 2018 Jun;32(6):601-640. doi: 10.1177/0269881118776738. Epub 2018 Jun 8.
  3. Psychosis and schizophrenia in adults: treatment and management; NICE Clinical Guideline (Feb 2014 - last updated March 2014)
  4. Powney MJ, Adams CE, Jones H; Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation). Cochrane Database Syst Rev. 2012 Nov 14;11:CD009377. doi: 10.1002/14651858.CD009377.pub2.
  5. Du M, Wang X, Yin S, et al; De-escalation techniques for psychosis-induced aggression or agitation. Cochrane Database Syst Rev. 2017 Apr 3;4:CD009922. doi: 10.1002/14651858.CD009922.pub2.

Article history

The information on this page is written and peer reviewed by qualified clinicians.

symptom checker

Feeling unwell?

Assess your symptoms online for free